Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.

被引：0
|
作者：
Papandreou, CN
Pagliaro, L
Millikan, R
Daliani, D
Herrmann, J
Hong, Y
Smith, M
Adams, J
Elliot, P
Lightcap, E
McCormack, T
Pien, C
Newman, R
Logothetis, CJ
机构：
[1] Univ Texas, Dept Genitourinary Med Oncol, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Leukosite Inc, Cambridge, MA 02139 USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页码：3730S / 3730S
页数：1
相关论文
共 50 条
  • [1] PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies.
    Stinchcombe, TE
    Mitchell, BS
    Depcik-Smith, N
    Adams, J
    Elliott, P
    Shea, TC
    Orlowski, RZ
    [J]. BLOOD, 2000, 96 (11) : 516A - 516A
  • [2] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [3] Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies.
    Orlowski, RZ
    Hall, M
    Voorhees, P
    Hogan, C
    Humes, E
    Johri, A
    Bell, H
    Garcia, R
    Adams, J
    Esseltine, D
    Gabriel, D
    Shea, T
    Van Deventer, H
    Mitchell, B
    Dees, EC
    [J]. BLOOD, 2002, 100 (11) : 105A - 105A
  • [4] A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Sumithra J. Mandrekar
    Steven R. Alberts
    Gary A. Croghan
    Aminah Jatoi
    Joel M. Reid
    Lorelei J. Hanson
    Laura Bruzek
    Angelina D. Tan
    Henry C. Pitot
    Charles Erlichman
    John J. Wright
    Alex A. Adjei
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 59 : 207 - 215
  • [5] A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Ma, Cynthia
    Mandrekar, Sumithra J.
    Alberts, Steven R.
    Croghan, Gary A.
    Jatoi, Aminah
    Reid, Joel M.
    Hanson, Lorelei J.
    Bruzek, Laura
    Tan, Angelina D.
    Pitot, Henry C.
    Erlichman, Charles
    Wright, John J.
    Adjei, Alex A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (02) : 207 - 215
  • [6] A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Aghajanian, C
    Soignet, S
    Dizon, DS
    Pien, CS
    Adams, J
    Elliott, PJ
    Sabbatini, P
    Miller, V
    Hensley, ML
    Pezzulli, S
    Canales, C
    Daud, A
    Spriggs, DR
    [J]. CLINICAL CANCER RESEARCH, 2002, 8 (08) : 2505 - 2511
  • [7] Proteasome inhibition by PS-341: A phase I study.
    Hamilton, A
    Eder, JP
    Pavlick, A
    Clark, JW
    Chachoua, A
    Ryan, DP
    Farrell, K
    Wasserstrom, H
    Liebes, L
    Wright, J
    Elliott, P
    Adams, J
    Muggia, F
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
  • [8] Development of the proteasome inhibitor PS-341
    Adams, J
    [J]. ONCOLOGIST, 2002, 7 (01): : 9 - 16
  • [9] The proteasome inhibitor PS-341 in cancer therapy
    Teicher, BA
    Ara, G
    Herbst, R
    Palombella, VJ
    Adams, J
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2638 - 2645
  • [10] Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    Shah, MH
    Young, D
    Kindler, HL
    Webb, I
    Kleiber, B
    Wright, J
    Grever, M
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6111 - 6118
12345